Navigation Links
ExonHit Therapeutics Shareholders' Equity Strengthened by Exercise of More Than Half of its Convertible Bonds
Date:3/8/2009

pre-clinical compounds. ExonHit Therapeutics also has a strategic partnership with Allergan, to discover and develop new therapeutics in the areas of pain, neurological diseases and ophthalmology. This collaboration provides on-going research funding to ExonHit.

Founded in 1997, ExonHit is headquartered in Paris, France and has a U.S. facility in Gaithersburg, Maryland. The Company is listed on Alternext of Euronext Paris (ISIN: FR0004054427; ticker: ALEHT) since November 17, 2005. For more information, please visit http://www.exonhit.com.

Disclaimer

This press release contains elements that are not historical facts including, without limitation, certain statements on future expectations and other forward-looking statements. Such statements are based on management's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.


'/>"/>
SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
2. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
3. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
4. ExonHit and bioMerieux Amend Their Strategic Partnership
5. ExonHit Builds A New Organisation
6. ExonHit Therapeutics - 2007 Financial Results
7. ExonHit Appoints a New Management Board
8. Frederic Desdouits Appointed Member of the Supervisory Board of ExonHit Therapeutics
9. ExonHit Launches Rat Genome SpliceArray(TM) Products to Expand High Resolution Gene Expression Profiling for use in Disease Modeling and Toxicogenomics
10. Loic Maurel Joins Exonhit Therapeutics to Become CEO
11. ExonHit Launches Mouse Genome SpliceArray(TM) for use in Human Disease Modeling Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... , September 18, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced ... Materials - Global Strategic Business Report" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the ... US$ Million by the following Product ...
(Date:9/18/2014)... 2014 On Tuesday, Secretary of Energy ... Risch for National Lab Day on the Hill. The ... national laboratory system. Durbin and Risch also formally launched ... awareness of the reach of the national labs as ... address some of our nation's most pressing challenges. , ...
(Date:9/18/2014)... Research and Markets has ... Industry Report 2014" report to their offering. ... 2014 is a professional and in-depth study on ... The report provides a basic overview ... industry chain structure. The N-acetylcysteine market analysis is ...
(Date:9/18/2014)... Research and Markets has announced the addition ... In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to ... The global companion diagnostics market is expected to grow ... Factors such as rising need for personalized medicine in ... pharmaceutical industry, support from regulatory authorities, and emerging technologies ...
Breaking Biology Technology:Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 2Lab Day Highlight Labs' Contribution to U.S. Competitiveness and Innovation 3Global N-acetylcysteine Industry Report 2014 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 2Global Companion Diagnostics (Polymerase Chain Reaction, In-situ hybridization, Immunohistochemistry) Market - Trends & Forecasts to 2019 3
... Therapeutics (CTI),(Nasdaq and MTA: CTIC) announced today that it ... exchange for 6,634 shares of CTI,s Series A, B ... interest of all,series of CTI,s Convertible Preferred Stock. Each ... 7,143 shares of CTI,s common stock, at a,conversion price ...
... $65.0 MillionRICHMOND, Calif., Feb. 4 Sangamo BioSciences, Inc. (Nasdaq: ... year 2008 financial results and accomplishments and provided an outlook ... Sangamo reported a consolidated net loss of $2.6 million, or ... million, or $0.17 per share, for the same period in ...
... Specialty Pharmacy is,pleased to announce two new "Navigator" ... DSP launched both a Hemophilia and IVIG,Navigator Program. ... as National,Sales Manager for both programs. Reed is ... over 18 years of pharmaceutical sales experience. Most ...
Cached Biology Technology:Cell Therapeutics Exchanges 83% of Remaining Convertible Preferred Stock Into New Non-dividend Bearing, Non-redeemable Convertible Preferred Stock With Conversion Price of $0.14 per Share 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 4Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 5Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 6Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 7Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 8Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 9Sangamo BioSciences Reports Fourth Quarter and Full Year 2008 Financial Results 10Diplomat Specialty Pharmacy Expands National Hemophilia & IVIG Program 2
(Date:9/21/2014)... developed a protein therapy that disrupts the process that ... sites, travel through the blood stream and start aggressive ... known as metastasis, can cause cancer to spread with ... succumb to cancer fall prey to metastatic forms of ... bioengineering who describes a new therapeutic approach in ...
(Date:9/19/2014)... A University of Oklahoma biology professor will study ... control leg movements with a National Science Foundation ... four-year project. , Ari Berkowitz, professor in the ... Sciences, will focus on the differences between the ... understand what neurotransmitters they use and what connections ...
(Date:9/19/2014)... new study shows that legume plants regulate their ... molecules that are transmitted through the plant structure ... number of bacteria-holding nodules in the roots. This ... National Institute for Basic Biology, the Graduate University ... for Sustainable Resource Science in Japan. , ...
Breaking Biology News(10 mins):Stanford researchers create 'evolved' protein that may stop cancer from spreading 2Stanford researchers create 'evolved' protein that may stop cancer from spreading 3Stanford researchers create 'evolved' protein that may stop cancer from spreading 4For legume plants, a new route from shoot to root 2
... brain that controls insulin responses has been shown to ... evidence that the disease can be treated in its ... Rhode Island Hospital and Brown Medical School. , ... prevent several components of neurodegeneration and preserve learning and ...
... known that animals use song as a way of attracting ... unusual way of scaring off predators ?by singing to them. ... that wild gibbons in Thailand have developed a unique song ... survival, the gibbons appear to use the song not just ...
... 21 September, 2006 - Elsevier is delighted to ... the journal Vaccine: HPV Vaccines and Screening in ... provides a comprehensive and invaluable update for paediatricians, ... major donor institutions worldwide. , With the arrival ...
Cached Biology News:Insulin receptor stops progression of Alzheimer's disease 2Insulin receptor stops progression of Alzheimer's disease 3Singing for survival 2Singing for survival 3
ANTI NO-TRYPTOPHAN CONJUGATE...
ANTI DEOXY CORTICO...
... and 2.0 mL samples for freezing point determinations. Includes built-in printer, keypad, ... with optional scanner. RS-232 port. Microprocessor-controlled autocalibration. Two-step Calibration. ... ... ...
Secure-Seal™ hybridization chamber gasket, eight chambers, 9 mm diameter, 0.8 mm deep *set of 20*...
Biology Products: